News
We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha said.
AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over 375 clinical trials. See why ABBV stock is a Buy.
AbbVie is undervalued with strong EPS growth, rising immunology revenue, and a 3.43% yield. Check out ABBV's robust pipeline and long-term value.
AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs.
AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. The collaboration ...
The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...
6d
Pharmaceutical Technology on MSNBig pharma braces for revenue headwinds as patent expiries loomA company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...
PORTLAND, OR, UNITED STATES, July 3, 2025 /EINPresswire / -- (Global value: USD 5.4 billion (2021) → USD 7.9 b ...
The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results